Literature DB >> 24900862

Phenylalanine-Based Inactivator of AKT Kinase: Design, Synthesis, and Biological Evaluation.

Thuy Nguyen1, Robert A Coover1, Jenson Verghese1, Richard G Moran2, Keith C Ellis1.   

Abstract

Strategies to inhibit kinases by targeting the substrate binding site offer many advantages, including naturally evolved selectivity filters, but normally suffer from poor potency. In this work we propose a strategy to design and prepare covalent substrate-competitive kinase inhibitors as a method to improve potency. We have chosen AKT as the model kinase for this work. Using the AKT-GSK3β cocrystal structure and a reactive cysteine near the substrate binding site, we have identified phenylalanine (Phe) as an appropriate scaffold for the covalent inactivator portion of these inhibitors. By synthesizing compounds that incorporate cysteine-reactive electrophiles into phenylalanine and testing these compounds as AKT inhibitors, we have identified Boc-Phe-vinyl ketone as a submicromolar inactivator of AKT. We also show that Boc-Phe-vinyl ketone (1) potently inhibits AKT1 and inhibits cell growth in HCT116 and H460 cells nearly as well as AKT inhibitors GSK690693 and MK-2206, (2) is selective for kinases that possess an activation loop cysteine such as AKT, (3) requires the vinyl ketone for inactivation, (4) has inactivation that is time-dependent, and (5) alkylates Cys310 of AKT as shown by mass spectrometry. Identification of Boc-Phe-vinyl ketone as a covalent inactivator of AKT will allow the development of peptide and small-molecule substrate-competitive covalent kinase inhibitors that incorporate additional substrate binding elements to increase selectivity and potency. This proof-of-principle study also provides a basis to apply this strategy to other kinases of the AGC and CAMK families.

Entities:  

Keywords:  AKT kinase; covalent inhibitor; substrate competitive

Year:  2014        PMID: 24900862      PMCID: PMC4027749          DOI: 10.1021/ml500088x

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  26 in total

Review 1.  The development and therapeutic potential of protein kinase inhibitors.

Authors:  P Cohen
Journal:  Curr Opin Chem Biol       Date:  1999-08       Impact factor: 8.822

2.  Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Authors:  Ogechi N Ikediobi; Helen Davies; Graham Bignell; Sarah Edkins; Claire Stevens; Sarah O'Meara; Thomas Santarius; Tim Avis; Syd Barthorpe; Lisa Brackenbury; Gemma Buck; Adam Butler; Jody Clements; Jennifer Cole; Ed Dicks; Simon Forbes; Kristian Gray; Kelly Halliday; Rachel Harrison; Katy Hills; Jonathan Hinton; Chris Hunter; Andy Jenkinson; David Jones; Vivienne Kosmidou; Richard Lugg; Andrew Menzies; Tatiana Mironenko; Adrian Parker; Janet Perry; Keiran Raine; David Richardson; Rebecca Shepherd; Alex Small; Raffaella Smith; Helen Solomon; Philip Stephens; Jon Teague; Calli Tofts; Jennifer Varian; Tony Webb; Sofie West; Sara Widaa; Andy Yates; William Reinhold; John N Weinstein; Michael R Stratton; P Andrew Futreal; Richard Wooster
Journal:  Mol Cancer Ther       Date:  2006-11-06       Impact factor: 6.261

Review 3.  Recent advances in designing substrate-competitive protein kinase inhibitors.

Authors:  Ki-Cheol Han; So Yeon Kim; Eun Gyeong Yang
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Bisubstrate inhibitors of protein kinases: from principle to practical applications.

Authors:  Darja Lavogina; Erki Enkvist; Asko Uri
Journal:  ChemMedChem       Date:  2010-01       Impact factor: 3.466

5.  Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP.

Authors:  Jing Yang; Peter Cron; Valerie M Good; Vivienne Thompson; Brian A Hemmings; David Barford
Journal:  Nat Struct Biol       Date:  2002-12

6.  Peptide and protein library screening defines optimal substrate motifs for AKT/PKB.

Authors:  T Obata; M B Yaffe; G G Leparc; E T Piro; H Maegawa; A Kashiwagi; R Kikkawa; L C Cantley
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

7.  Preparation and evaluation of deconstruction analogues of 7-deoxykalafungin as AKT kinase inhibitors.

Authors:  Sudha Korwar; Thuy Nguyen; Keith C Ellis
Journal:  Bioorg Med Chem Lett       Date:  2013-11-20       Impact factor: 2.823

8.  N-Ethylmaleimide inhibits platelet-derived growth factor BB-stimulated Akt phosphorylation via activation of protein phosphatase 2A.

Authors:  Chandrahasa R Yellaturu; Manjula Bhanoori; Indira Neeli; Gadiparthi N Rao
Journal:  J Biol Chem       Date:  2002-08-08       Impact factor: 5.157

9.  A novel substrate mimetic inhibitor of PKB/Akt inhibits prostate cancer tumor growth in mice by blocking the PKB pathway.

Authors:  Pninit Litman; Osnat Ohne; Shirly Ben-Yaakov; Liron Shemesh-Darvish; Tamar Yechezkel; Yosef Salitra; Shai Rubnov; Ilana Cohen; Hanoch Senderowitz; Dvora Kidron; Oded Livnah; Alexander Levitzki; Nurit Livnah
Journal:  Biochemistry       Date:  2007-03-31       Impact factor: 3.162

10.  Pseudosubstrate peptides inhibit Akt and induce cell growth inhibition.

Authors:  Yan Luo; Richard A Smith; Ran Guan; Xuesong Liu; Vered Klinghofer; Jianwei Shen; Charles Hutchins; Paul Richardson; Tom Holzman; Saul H Rosenberg; Vincent L Giranda
Journal:  Biochemistry       Date:  2004-02-10       Impact factor: 3.162

View more
  4 in total

1.  Characterization of PKACα enzyme kinetics and inhibition in an HPLC assay with a chromophoric substrate.

Authors:  Nicole M Luzi; Charles E Lyons; Darrell L Peterson; Keith C Ellis
Journal:  Anal Biochem       Date:  2017-06-05       Impact factor: 3.365

2.  Combining ligand- and structure-based in silico methods for the identification of natural product-based inhibitors of Akt1.

Authors:  Priya Mahajan; Bhumika Wadhwa; Manas Ranjan Barik; Fayaz Malik; Amit Nargotra
Journal:  Mol Divers       Date:  2019-02-23       Impact factor: 2.943

Review 3.  Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).

Authors:  George Mihai Nitulescu; Denisa Margina; Petras Juzenas; Qian Peng; Octavian Tudorel Olaru; Emmanouil Saloustros; Concettina Fenga; Demetrios Α Spandidos; Massimo Libra; Aristidis M Tsatsakis
Journal:  Int J Oncol       Date:  2015-12-24       Impact factor: 5.650

4.  Targeting allosteric site of AKT by 5,7-dimethoxy-1,4-phenanthrenequinone suppresses neutrophilic inflammation.

Authors:  Po-Jen Chen; I-Ling Ko; Chia-Lin Lee; Hao-Chun Hu; Fang-Rong Chang; Yang-Chang Wu; Yann-Lii Leu; Chih-Ching Wu; Cheng-Yu Lin; Chang-Yu Pan; Yung-Fong Tsai; Tsong-Long Hwang
Journal:  EBioMedicine       Date:  2019-01-30       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.